Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid esters
- Development stage
- Unknown
- Lead developer
- Wroclaw Medical University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of essential polyunsaturated fatty acid (EFA) esters, specifically alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Developed by Wroclaw Medical University, this formulation is being investigated in the Phase 3 OMEGA trial for the prevention of cardiovascular diseases in adults. The mechanism of action involves the activation of peroxisome proliferator-activated receptors (PPARs) and free fatty acid receptors, which leads to improved lipid profiles (increased HDL and decreased LDL cholesterol) and reduced systemic inflammation. ALA is particularly noted for its anti-inflammatory properties and its status as an essential fatty acid that cannot be synthesized by the human body. The study aims to evaluate the efficacy of these combined esters in reducing risk factors for atherosclerosis, stroke, and myocardial infarction by modulating metabolic and inflammatory pathways.
- Other names
- Fatty Acids, UnsaturatedALA + EPA + DHA estersEssential Polyunsaturated Fatty Acid EstersOMEGA EFA Esters
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on alpha-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid esters.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-linolenic acid + eicosapentaenoic acid + docosahexaenoic acid esters.